60 Degrees Pharmaceuticals, Inc. · NASDAQ:SXTP
60 Degrees Pharmaceuticals — H.C. Wainwright Conference (September 2025)
19 slides from 60 Degrees Pharmaceuticals's conference presentation, September 2025
Slide 1: H.C. Wainwright Presentation
H.C. Wainwright Presentation Investment focus 60 Degrees Pharmaceuticals, Inc. A marketed antimalarial platform creates a path to potential indication expansion in babesiosis September 2025 Commercial base ARAKODA® malaria prophylaxis Clinical vector Babesiosis development program Regulatory arc sND
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Important factors that could cause our actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt DISCLAIMER. The information contained
Slide 3: Investment Thesis
Investment Thesis A marketed antimalarial platform creates a staged path to potential indication expansion in babesiosis. Core thesis 1 Commercial base 2 Lead expansion ARAKODA® is already marketed for Babesiosis is the focused Label expansion of ARAKODA® / malaria prophylaxis, providing development
Slide 4: Financial Snapshot
Financial Snapshot Q2 2026 results + July financing / Knight conversion Q2 10-Q filed Aug. 14, 2026 COMMON OUTSTANDING/MARKET CAP PREFERRED OUTSTANDING COMMON WARRANTS PRE-FUNDED WARRANTS ~3.51M/ ~4M 68,080 ~3.09M 383.1k Pro forma at Jul. 31: 2.659M base + 658.6k Knight conversion + 191.6k common is
Slide 5: Ticks Transmit a Widening Set of Serious Diseases in the U.S.
Ticks Transmit a Widening Set of Serious Diseases in the U.S. Record tick-bite emergency room visits in 2026 underscore the rising need for targeted therapies. Examples of diseases transmitted or associated with U.S. ticks ER visits for tick bites Lyme disease Anaplasmosis RECORD LEVELS Relapsing fe
Slide 6: Critical Unmet Need in Selected Tick-Borne and Tick-Associated Diseases
Critical Unmet Need in Selected Tick-Borne and Tick-Associated Diseases High burden, limited approved options, and a clear rationale for small-molecule repositioning Babesiosis Post-Treatment Lyme Disease Alpha-Gal Syndrome Parasitic red-blood-cell infection Chronic disease following acute infection
Slide 7: Portfolio August 2026
Portfolio August 2026 PHASES AND DEVELOPMENT STAGES IND ENABLING REGULATORY COMMERCIALLY COMMERCIALLY PRODUCT NON-CLINICAL PHASE IIA Phase IIB/III PHASE 1 REVIEW AVAILABLE SUSTAINABLE ARAKODA® (US) ZAMVIO (tafenoquine): TICK-BORNE DISEASE – VETERINARY INDICATIONS Preparing dossier for FDA meeting Mu
Slide 8: Chronic / severe fatigue
Chronic / Persistent fatigue may drive severe prolonged recovery fatigue Source: CDC signs/symptoms of babesiosis. 8
Slide 9: Babesiosis Treatment Gap
Babesiosis Treatment Gap Current regimens leave a high-need refractory segment with limited evidence and no FDA-approved options. STANDARD OF CARE TODAY WHY THIS MATTERS REPOSITIONING RATIONALE First-line treatment <30% 0 cure rate of atovaquone-based specific FDA-approved New treatment option Atova
Slide 10: Babesiosis: An Orphan Disease With Three Distinct Unmet Need Segments
Babesiosis: An Orphan Disease With Three Distinct Unmet Need Segments Hospitalized acute disease, refractory immunosuppressed disease, and chronic/persistent symptoms create multiple treatment opportunities. Severe Disease ! Persistent Disease R Chronic Disease C Hospitalization Immunosuppressed pat
Slide 11: Indicated for prophylaxis of malaria in adults
2018 2019 commercially US FDA approval available adult age group indicated 52 weeks 8 >1,100 patients AE rate comparable to placebo; G6PD studies Indicated for prophylaxis of malaria in adults screening required. 11
Slide 12: Tafenoquine & Babesiosis: Non-Clinical Proof of Concept
Tafenoquine & Babesiosis: Non-Clinical Proof of Concept Blood-smear phenotype plus SCID-mouse combination data support repositioning into Babesia. BLOOD-SMEAR PHENOTYPE (LIU ET AL.) MECHANISTIC + COMBINATION TAKEAWAYS Blood-smear signal 1 Tafenoquine-treated Babesia showed a distinct RBC phenotype c
Slide 13: Treatment-Refractory Babesiosis: Human Case-Series Signal
Treatment-Refractory Babesiosis: Human Case-Series Signal Tafenoquine combinations cured 4 of 4 immunosuppressed patients when administered concurrently for >8 weeks. >8 wks concurrent tafenoquine + atovaquone + antibiotic combinations 1 Human signal Cure observed in difficult-to-treat immunosuppres
Slide 14: Babesiosis Could Triple the ARAKODA Asset Opportunity
Babesiosis Could Triple the ARAKODA® Asset Opportunity Patient exclusivity creates two ways to expand the same marketed antimalarial platform: treated patients and treatment-course value. PATIENT CASELOAD OPPORTUNITY VALUE OPPORTUNITY AT CURRENT WAC Maximum cumulative addressable market (2026Q3–2035
Slide 15: Tafenoquine + SOC vs placebo + SOC
Tafenoquine + SOC vs placebo + SOC TQ dose: 200 mg × 4, then 200 mg weekly for 4 weeks NAT test used to define cure Primary: TTSCR* 200 mg weekly following the load through Day 90 *TTSCR = time to sustained clinical resolution; TTMC = time to molecular cure. 15
Slide 16: Objective: Align with FDA on NAT as a relapse surrogate
Objective: Align with FDA on NAT as a relapse surrogate and a confirmatory-study path that can support indication expansion. 16
Slide 17: FDA precedent: Wellcovorin/leucovorin supplemental approval
Sources: FDA press announcement and supplemental approval materials for Wellcovorin/leucovorin calcium (Mar. 2026). 17
Slide 18: Derisked Regulatory Pathway: Regular sNDA
Derisked Regulatory Pathway: Regular sNDA Hospital study efficacy plus expanded access cure data could support lower risk regulatory approval pathway 18
Slide 19: Anticipated Milestones
OTHER ANTICIPATED OTHER MILESTONES ANTICIPATED MILESTONES New product collaborations • market updates • other product research updates Potential Potential PDUFAdate PDUFA date with priority review with priority review 19 19
60 Degrees Pharmaceuticals — H.C. Wainwright Conference (September 2025) on 6ix